Abstract at IgMin Research

Our mission is to foster interdisciplinary dialogue and accelerate the advancement of knowledge across a wide spectrum of scientific domains.

LC-MS and HPLC-UV for Detecting Uremic Toxins: Two Validated Methods with Simultaneous Sensitivity and Specificity Evaluation



    Biofordrug, Spin-off dell’Università degli Studi di Bari, via Dante 99, 70019, Triggiano, Bari, Italy

    Biofordrug, Spin-off dell’Università degli Studi di Bari, via Dante 99, 70019, Triggiano, Bari, Italy


Uremic toxins (UTs) are compounds derived from the metabolism of dietary molecules such as tryptophan (Indossyl Sulphate, IS) and phenil-alanine (P-Cresyl Sulphate, PCS), that are normally eliminated by the kidneys of healthy patients. The accumulation of such toxins is an indicator of kidney disease at different degrees of severity, and the toxins can be found as free or protein bound in human biological samples. The toxicity of such compounds causes the loss of several biological functions, and the subjects suffering from such complications will need, more often than not, hemodialysis to properly excrete these toxins. Despite this not being a resolutive, but rather a symptom managing clinical approach, this is the most common course of treatment. Two analytical methods are proposed to quantify both the protein-bound and free forms of IS and PCS (HPLC-UV for the former; LC-MS/MS with ESI negative ionization for the latter), with lower variability and higher robustness than what is currently proposed, allowing for a precise simultaneous determination of the aforementioned UTs.



    1. Regunathan-Shenk R, Shah NB, Raj DS. Chapter 11-the gut microbiome and the kidney. Nutritional Management of Renal Disease (Fourth Edition). 2022; 147-161.
    2. Karadsheh FF, Weir MR. Chapter 23 - Hematologic Complications of Chronic Kidney Disease: Leukocyte and Monocyte Function, Hematologic Complications of Chronic Kidney Disease. Chronic Renal Disease. 2015; 277-284.
    3. Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management: A Review. JAMA. 2019 Oct 1;322(13):1294-1304. doi: 10.1001/jama.2019.14745. PMID: 31573641; PMCID: PMC7015670.
    4. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW. Chronic kidney disease: global dimension and perspectives. Lancet. 2013 Jul 20;382(9888):260-72. doi: 10.1016/S0140-6736(13)60687-X. Epub 2013 May 31. Erratum in: Lancet. 2013 Jul 20;382(9888):208. PMID: 23727169.
    5. Falconi CA, Junho CVDC, Fogaça-Ruiz F, Vernier ICS, da Cunha RS, Stinghen AEM, Carneiro-Ramos MS. Uremic Toxins: An Alarming Danger Concerning the Cardiovascular System. Front Physiol. 2021 May 14;12:686249. doi: 10.3389/fphys.2021.686249. PMID: 34054588; PMCID: PMC8160254.
    6. Vanholder R, De Smet R, Glorieux G, Argilés A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jörres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W; European Uremic Toxin Work Group (EUTox). Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003 May;63(5):1934-43. doi: 10.1046/j.1523-1755.2003.00924.x. Erratum in: Kidney Int. 2020 Nov;98(5):1354. PMID: 12675874.
    7. Evenepoel P, Meijers BK, Bammens BR, Verbeke K. Uremic toxins originating from colonic microbial metabolism. Kidney Int Suppl. 2009 Dec;(114):S12-9. doi: 10.1038/ki.2009.402. PMID: 19946322.
    8. Caldiroli L, Armelloni S, Eskander A, Messa P, Rizzo V, Margiotta E, Cesari M, Vettoretti S. Association between the uremic toxins indoxyl-sulfate and p-cresyl-sulfate with sarcopenia and malnutrition in elderly patients with advanced chronic kidney disease. Exp Gerontol. 2021 May;147:111266. doi: 10.1016/j.exger.2021.111266. Epub 2021 Jan 30. PMID: 33529747.
    9. Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, Choukroun G, Vanholder R, Massy ZA; European Uremic Toxin Work Group (EUTox). Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol. 2009 Oct;4(10):1551-8. doi: 10.2215/CJN.03980609. Epub 2009 Aug 20. PMID: 19696217; PMCID: PMC2758258.
    10. Niwa T, Ise M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med. 1994 Jul;124(1):96-104. PMID: 8035108.
    11. Korytowska N, Wyczałkowska-Tomasik A, Pączek L, Giebułtowicz J. Evaluation of Salivary Indoxyl Sulfate with Proteinuria for Predicting Graft Deterioration in Kidney Transplant Recipients. Toxins (Basel). 2021 Aug 16;13(8):571. doi: 10.3390/toxins13080571. PMID: 34437442; PMCID: PMC8402605.
    12. Fabresse N, Larabi IA, Abe E, Lamy E, Rigothier C, Massy ZA, Alvarez JC. Correlation between Saliva Levels and Serum Levels of Free Uremic Toxins in Healthy Volunteers. Toxins (Basel). 2023 Feb 13;15(2):150. doi: 10.3390/toxins15020150. PMID: 36828466; PMCID: PMC9967652.
    13. Gryp T, Vanholder R, Vaneechoutte M, Glorieux G. p-Cresyl Sulfate. Toxins (Basel). 2017 Jan 29;9(2):52. doi: 10.3390/toxins9020052. PMID: 28146081; PMCID: PMC5331431.
    14. Pretorius CJ, McWhinney BC, Sipinkoski B, Johnson LA, Rossi M, Campbell KL, Ungerer JP. Reference ranges and biological variation of free and total serum indoxyl- and p-cresyl sulphate measured with a rapid UPLC fluorescence detection method. Clin Chim Acta. 2013 Apr 18;419:122-6. doi: 10.1016/j.cca.2013.02.008. Epub 2013 Feb 18. PMID: 23428591.
    15. Yousef Selim N, Farag Mannaa H, Atef Sharaki O, Zaytoun T, Elkholy N, Arafat W. Highlighting Levels of Indoxyl Sulphate among Critically Ill Patients with Acute Nephrotoxicity; Correlations Between Indoxyl Sulphate Levels and Patients' Characteristics. Rep Biochem Mol Biol. 2021 Jul;10(2):266-279. doi: 10.52547/rbmb.10.2.266. PMID: 34604416; PMCID: PMC8480295.
    16. Boelaert J, Lynen F, Glorieux G, Eloot S, Van Landschoot M, Waterloos MA, Sandra P, Vanholder R. A novel UPLCMS-MS method for simultaneous determination of seven uremic retention toxins with cardiovascular relevance in chronic kidney disease patients. Anal Bioanal Chem. 2013; 405: 1937–1947.
    17. Lin CJ, Chen HH, Pan CF, Chuang CK, Wang TJ, Sun FJ, Wu CJ. p-Cresylsulfate and indoxyl sulfate level at different stages of chronic kidney disease. J Clin Lab Anal. 2011;25(3):191-7. doi: 10.1002/jcla.20456. PMID: 21567467; PMCID: PMC6647585.
    18. Cuoghi A, Caiazzo M, Bellei E, Monari E, Bergamini S, Palladino G, Ozben T, Tomasi A. Quantification of p-cresol sulphate in human plasma by selected reaction monitoring. Anal Bioanal Chem. 2012 Oct;404(6-7):2097-104. doi: 10.1007/s00216-012-6277-z. Epub 2012 Aug 7. PMID: 22868475.

Similar Articles

System for Detecting Moving Objects Using 3D Li-DAR Technology
Md. Milon Rana, Orora Tasnim Nisha, Md. Mahabub Hossain, Md Selim Hossain, Md Mehedi Hasan and Md Abdul Muttalib Moon
Peritoneal Carcinomatosis from Ovarian Cancer: A Case Report
Andrea González De Godos, Enrique Asensio Diaz, Pilar Pinto Fuentes, Baltasar Pérez Saborido and David Pacheco Sánchez
Integrated Multi-fidelity Structural Optimization for UAV Wings
Sanusi Muhammad Babansoro, Deng Zhongmin, Hasan Mehedi and SM Tarikul Islam